Global Aminosalicylates and Zoledronic Acid Markets Projected to Reach $4.7B and $15.9B by 2032

Data Bridge Market Research reports that the global aminosalicylates market was valued at $2.80 billion in 2024 and is forecast to grow to $4.70 billion by 2032, a compound annual growth rate (CAGR) of 6.70%. The market is driven by rising prevalence of inflammatory bowel diseases, with mesalamine holding the largest share.

The same firm projects the global zoledronic acid market at $9.80 billion in 2024, expanding to $15.85 billion by 2032 at a 6.20% CAGR. Osteoporosis and bone metastases are the primary indications, and both branded and generic segments are expected to compete for market share. Key players cited include Novartis AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., and Piramal Healthcare.